GEO Publications
Handout
NAR 2024 (latest)
NAR 2002 (original)
All publications
FAQ
MIAME
Email GEO
NCBI
>
GEO
>
Accession Display
Not logged in |
Login
GEO help:
Mouse over screen elements for information.
Scope:
Self
Platform
Samples
Series
Family
Format:
HTML
SOFT
MINiML
Amount:
Brief
Quick
GEO accession:
Sample GSM39502
Query DataSets for GSM39502
Status
Public on Apr 01, 2005
Title
pp122-5
Sample type
RNA
Source name
Staged C. elegans embryos
Organism
Caenorhabditis elegans
Extracted molecule
total RNA
Description
Mutant genotype pie-1(zu154); pal-1(RNAi) 122 minutes after the 4-cell embryonic stage at 22 degrees C
Sample_genotype: pp
Sample_time: 122
Submission date
Jan 24, 2005
Last update date
May 27, 2005
Contact name
Andrew Hill
E-mail(s)
andrew.hill@pfizer.com
Phone
617-674-6341
Organization name
Pfizer
Department
Research Business Technology
Street address
300 Technology Square
City
Cambridge
State/province
MA
ZIP/Postal code
02139
Country
USA
Platform ID
GPL200
Series (1)
GSE2180
C. elegans embryonic timecourse in wt and mutant embryos
Data table header descriptions
ID_REF
Affymetrix Qualifier
VALUE
RMA calulated using Bioconductor Affy package (http://www.bioconductor.org)
Data table
ID_REF
VALUE
171720_x_at
3.55568599985378
171721_x_at
6.79200365671882
171722_x_at
6.627254768667
171723_x_at
3.40528584817397
171724_x_at
3.62884097739262
171725_x_at
4.37182095901057
171726_x_at
4.53746139016677
171727_x_at
2.80046268193791
171728_x_at
2.77090087924351
171729_x_at
7.31503877479536
171730_x_at
2.98706579997221
171731_x_at
8.22350125567043
171732_x_at
6.52513225667699
171733_x_at
10.7372177909342
171734_x_at
9.26274048791359
171735_x_at
3.21816568209638
171736_x_at
8.18794349824453
171737_x_at
8.87494206999157
171738_x_at
7.07185220914368
171739_x_at
3.25412646314257
Total number of rows:
22625
Table truncated, full table size
608 Kbytes
.
Supplementary file
Size
Download
File type/resource
GSM39502.CEL.gz
3.0 Mb
(ftp)
(http)
CEL
GSM39502.EXP.gz
332 b
(ftp)
(http)
EXP
|
NLM
|
NIH
|
GEO Help
|
Disclaimer
|
Accessibility
|
